Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options

Rhea-AI Filing Summary

Ovid Therapeutics Inc. director Anna Greka received a grant of stock options covering 130,000 shares of common stock. The options have an exercise price of $2.26 per share and expire on June 14, 2036.

According to the grant terms, the 130,000 underlying shares vest in 36 equal monthly installments starting on July 15, 2026, contingent on her continued service with the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Greka Anna

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	130,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 130,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 130,000 options Exercise price: $2.26 per share Underlying shares: 130,000 shares +2 more

5 metrics

Stock options granted 130,000 options Grant to director Anna Greka

Exercise price $2.26 per share Stock option strike price

Underlying shares 130,000 shares Common stock underlying the options

Option expiration June 14, 2036 Option term end date

Vesting schedule 36 monthly installments Commencing July 15, 2026

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 2.2600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-14T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"will vest in 36 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greka Anna

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.26	06/15/2026		A		130,000		(1)	06/14/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date.

	/s/ Jeffrey Rona, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OVID director Anna Greka report?

Director Anna Greka reported receiving a grant of stock options for 130,000 Ovid Therapeutics common shares. This award is a compensation-related acquisition, not an open-market trade, and gives her the right to buy shares at a fixed exercise price over time.

What is the exercise price of Anna Greka’s OVID stock options?

The granted stock options have an exercise price of $2.26 per share. This means she can buy up to 130,000 Ovid Therapeutics common shares at $2.26, subject to vesting and before the options expire on June 14, 2036.

How do the 130,000 OVID stock options granted to Anna Greka vest?

The 130,000 stock options vest in 36 equal monthly installments beginning July 15, 2026. Each month, a portion becomes exercisable, provided Anna Greka continues to provide services to Ovid Therapeutics through each respective vesting date.

When do Anna Greka’s OVID stock options expire?

The stock options granted to Anna Greka expire on June 14, 2036. She may exercise vested options any time before this expiration date, subject to the plan’s terms and her continued eligibility under Ovid Therapeutics’ equity arrangements.

Is Anna Greka’s Form 4 filing for OVID a stock purchase or sale?

The Form 4 reflects a grant of stock options, not a market purchase or sale. The transaction code A indicates a grant or award, giving her rights to acquire Ovid Therapeutics shares in the future at a fixed exercise price.